Induct - Significant contract signed with leading UK NHS Hospital Trust

Portsmouth Hospitals NHS Trust is the first NHS Trust in England to start using Induct's new click-based platform  

Chronically ill patients in the UK, with asthma (5.4 million) and chronic obstructive pulmonary disease (COPD), 1.2 million costs the NHS billions (GBP 800 million for COPD and or GBP 11 billion for lung disease in the UK annually) each year.  In order to improve the quality of care for its patients, Portsmouth Hospital NHS Trust (PHT) required a system that could manage and monitor patient progress, as well as improve communication between those involved in the patient’s care. Induct’s new platform has provided a solution to meet the need of the team engaged in designing and trialling improved care pathways for patient groups that has the potential to be rolled out in the future to benefit many.

“This is a significant step for Induct both in terms of its collaboration with the NHS but also in developing applications for its new, click-based platform with Google Advertising. Our success in the hospitals sector here in Norway is now being replicated in England", says Alf Martin Johansen, CEO of Induct.


Future potential

Users of the system, healthcare professionals and patients in the future, could number many millions which have the power to translate into a solid revenue base for Induct through the new click-based platform model which uses Google Advertising.

“On average, two dollars a month per user are spent on comparable platforms that are funded through advertising models. We believe that within two years our new platform will be used by, in excess, of a million users”, says Johansen.

PHT wants to implement the Induct platform in its improvement programmes as soon as possible.

Professor Anoop Chauhan, leading on the project says: “Firstly, and most importantly, the treatment of our patients will be improved that will translate into an increase in the quality of their lives.

“Secondly, by streamlining the clinical journey of the patients and centralising the documentation we will be able to better evaluate the clinical outcomes and improve research within the fields of asthma and COPD.

“Finally, chronically ill patients are a significant burden on the public purse.  Using the Induct platform we will be able to streamline the patient journey, improve the quality of care whilst at the same time reducing costs and saving valuable clinical time.”


Safe data storage

“Ensuring patient data is securely stored is a high priority for any company engaged in working with the NHS. The Induct platform met all of our criteria for this project and we are confident of its use for the purpose for which it will be used”, commented Anoop.

In the first area of application, Induct will support the NHS Trust with patient data management for patients suffering with asthma, COPD and breathlessness.

"The vision is to see our platform in routine use across many disease areas for the benefit of all patient groups. The potential is great and we are already in a dialogue with PHT about other areas for application”, says Johansen.

           

For further information, please contact:

Alf Martin Johansen, Chief Executive Officer
+47 90 17 94 35
amj@inductsoftware.com


About Induct

Based on eight years of collaboration with more than 250 organizations, Induct offers collaborative communities, delivered as "Software as a Service," that enable organizations to digitalize and manage business processes. This also include create, manage, track and measure the innovation process from idea creation through to final implementation and impact reporting. Induct enables its customers to connect with each other in larger networks to share best practices, while deploying and monetizing initiatives - all within a secure, collaborative, and access-controlled cloud-based network.

Subscriptions is the main source of income for Induct. Induct has customers in 9 countries.

Induct is listed on the Merkur Market list on the Oslo Stock Exchange with the ticker INDUCT-ME.

Tags:

Subscribe